Simulations Plus logo
SLPSimulations Plus
Trade SLP now
Simulations Plus primary media

About Simulations Plus

Simulations Plus (NASDAQ:SLP) specializes in creating simulation and modeling software for pharmaceutical research and development. With a focus on advancing drug discovery and development, the company offers a suite of software products designed to predict properties of molecules with high accuracy. These solutions enable researchers and biotech companies to make more informed decisions earlier in the drug development process, reducing time and costs associated with bringing new therapies to market. Simulations Plus also provides consulting services, leveraging its software capabilities to offer customized solutions that meet the specific needs of its clients. The company's objective is to remain at the forefront of technological innovation, continuously improving its offerings to support the evolving needs of the global pharmaceutical industry.

What is SLP known for?

Snapshot

Public US
Ownership
1996
Year founded
151
Employees
Lancaster, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Simulations Plus

  • GastroPlus® - software for the simulation of pharmacokinetics, pharmacodynamics, and drug absorption.
  • ADMET Predictor® - a tool for predicting the absorption, distribution, metabolism, excretion, and toxicity of chemicals.
  • DILIsym® - software for predicting drug-induced liver injury, aiding in the assessment of drug safety.
  • Kibos® - an AI-driven platform for clinical trial simulation and prediction, enhancing drug development strategies.
  • MonolixSuite® - a comprehensive solution for pharmacometric analyses, including population PK/PD modeling.
  • MembranePlus™ - software for simulating and predicting oral drug absorption and formulation performance.

Simulations Plus executive team

  • Mr. Shawn M. O'ConnorChief Executive Officer
  • Mr. William FrederickCFO, Executive VP & Corporate Secretary
  • Mr. Josh FoheyChief Operating Officer
  • Mr. John Anthony DiBella M.S.Chief Revenue Officer
  • Ms. Jill Fiedler-Kelly M.S.President of Services Solutions
  • Mr. Steven ChangGlobal Head of Strategic Alliances
  • Ms. Jennifer PresnellAccounting Manager
  • Ms. Viera Lukacova Ph.D.Chief Science Officer
  • Dr. Bud Nelson J.D., Ph.D.VP of Corporate Counsel & Personal Data Protection Officer
  • Ms. Christina HendricksonSenior Director of Corporate Marketing

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.